Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Primidone. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. Danazol may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. Paricalcitol may increase the arrhythmogenic activities of Ouabain. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The metabolism of Paricalcitol can be decreased when combined with Olaparib. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The metabolism of Paricalcitol can be decreased when combined with Clemastine. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. The metabolism of Paricalcitol can be increased when combined with Rifampicin. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The metabolism of Paricalcitol can be increased when combined with Nevirapine. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. Polythiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. Indapamide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. Quinethazone may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. Metolazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. The metabolism of Paricalcitol can be decreased when combined with Sildenafil.